Yael Cohen, MD, sat down with CancerNetwork® to discuss how the multiple myeloma space is entering into an era of CAR T-cell therapy.
Yael Cohen, MD, discusses safety data from a clinical trial assessing the use of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.
In an interview with CancerNetwork®, Yael Cohen, MD, discusses how treatment with ciltacabtagene autoleucel resulted in a high rate of minimal residual disease negativity in patients diagnosed with lenalidomide-refractory multiple myeloma.
Looking forward, Andrzej Jakubowiak, MD, PhD, anticipates CAR T-cell therapy with ciltacabtagene autoleucel will establish its place across various indications for multiple myeloma.
CancerNetwork®, sat down with Yael Cohen, MD, to discuss the research that lead up to the phase 2 CARTITUDE-2 trial, examining the use of ciltacabtagene autoleucel for those with lenalidomide–refractory multiple myeloma
In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, dives into response outcomes in different patient subsets of the phase 1/2b CARTITUDE-1 trial of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, describes how CAR T-cell therapy for patients with heavily pretreated myeloma has the potential significantly impact response and survival outcomes.
Patients with triple-class relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel saw a greater survival benefit over physician's choice of treatment.
Most subgroups of patients with relapsed or refractory, heavily pretreated multiple myeloma showed durable responses at the 2-year follow-up to the CARTITUDE-1 trial.
Deep responses were seen with single infusion ciltacabtagene autoleucel for heavily pretreated patients with multiple myeloma who were refractory to lenalidomide.